Infectious Disease Therapeutics Market

Infectious Disease Therapeutics Market by Disease Types (HIV [Aptivus, Selzentry, Emtriva, Lexiva/Telzir, Insentress, Tivicay, Complera, Odefseu, Atripla, Genvoya, Vitekta, Stribild, Descovy, Triumeq, Truvada, and Others], Malaria [Coartem, Others], TB [Sirturu, Others], Influenza [Tamiflu, Relenza, Rapivab, Others], HPV, and Hepatitis) and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021-2028

  • Report ID: HC-2230
  • Author: Growth Market Reports
  • Rating: 4.6
  • Total Reviews: 2
  • No. Of Pages: 215
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global infectious disease therapeutics market size is projected to register a substantial CAGR during the forecast period, 2021-2028 attributed to an increase in number of people affected with infectious diseases. One of the most important factors helping the market growth is the rise in clinical trials in order to develop new drugs that can be effective for the treatment of infectious diseases.

Infectious Disease Therapeutics Market

Infectious diseases are primarily caused by various organisms or microorganisms such as viruses, bacteria, parasites, and fungi. Some of the infectious diseases are transmitted from animals or insects and most of them are contagious as these diseases can be passed on from one person to another easily. In terms of the number of the infectious disease cases, Asia and Africa are the two major regions with a high prevalence of the cases but has low rate of treatment due to a lack of awareness among the people regarding the treatments available for such infectious diseases. According to a report published by AVERT, nearly 6.5 million were infected with Human Immunodeficiency Virus (HIV) in the Central and West African region in 2015 and 28% of people among those had access to antiretroviral therapy. Meanwhile, Africa has the largest number of people suffering from such infectious diseases, as per the report of the World Health Organization (WHO) and it suggests that around 90% of the global malaria deaths were reported in the region.

New generic products are being developed that are expected to replace the established branded drugs in the market being cost-effective constituting of same compositions and features. Professionals also prescribe drugs that are cost-effective and this is expected to fuel the market. For example, ISENTRESS HD a product by Merck received was approved by the US Food and Drugs Administration in May 2017 for patients who are infected with HIV-1. Another drug named RAPIVAB by BioCryst was approved by Health Canada in January 2017 for the treatment of individuals infected with Influenza.

Market Trends, Drivers, Restraints, and Opportunities

  • Expiration of several parents and introduction of generic drugs that constitute similar components as branded drugs is a key driving factor of the market.
  • Development of new products and increasing in the approval for the successful commercialization for such infectious diseases treatment is another key driving factor of the market.
  • Increase in investments and funding for research & development by pharmaceutical companies is a prominent market driver that expected to help the market growth in the coming years.
  • Rise in healthcare initiatives taken by government and non-profit organizations in order to spread awareness towards such infectious diseases is projected to boost the market growth.
  • Low rate for diagnosis and treatment of infectious diseases in developing countries and lack of awareness among people are the key restraining factors of the market.

Scope of the Report

The report on the global infectious disease therapeutics market includes an assessment of the market, trends, and segments. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Infectious Disease Therapeutics Market – Global Industry Analysis, Growth, Share, Size, Trends, And Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Disease Types (HIV [Aptivus, Selzentry, Emtriva, Lexiva/Telzir, Insentress, Tivicay, Complera, Odefseu, Atripla, Genvoya, Vitekta, Stribild, Descovy, Triumeq, Truvada, and Others], Malaria [Coartem, Others], TB [Sirturu, Others], Influenza [Tamiflu, Relenza, Rapivab, Others], HPV, and Hepatitis)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

GlaxoSmithKline PLC; Gilead; Novartis AG; Janssen Pharmaceutical, Inc.; Merck & Co. Inc.; F. Hoffmann-La Roche Ltd.;  Boehringer Ingelheim GmbH; and BioCryst Pharmaceuticals, Inc.

Market Segment Insights

HPV segment is expected to expand at a rapid pace

On the basis of disease types, the global infectious disease therapeutics market is divided into HIV, malaria, TB, influenza, HPV, and hepatitis. The HIV segment is further divided into aptivus, selzentry, emtriva, lexiva/telzir, insentress, tivicay, complera, odefseu, atripla, genvoya, vitekta, stribild, descovy, triumeq, truvada, and others. The malaria segment is bifurcated into coartem and others. The TB segment is further bifurcated into sirturu and others. The influenza segment is sub-divided into tamiflu, relenza, rapivab, and others. The HIV segment held a major share of the market in 2019 representing with more than 41.5% of the global market share and is expected to expand at a rapid pace in the coming years. The segment growth is attributed to an increase in the incidence of HIV, an increase in the number of awareness camps, a rise in the supply of self-test kits for HIV, and an increase in the number of activities to generate funding for patients infected with HIV.

Meanwhile, the hepatitis therapeutics market represented a large market share in 2019 and is anticipated to register a substantial CAGR during the forecast period. The segment growth is attributed to an increase in cases of hepatitis, an increase in the number of initiatives taken to increase the adoption of drugs, and a rise in clinical tries in order to develop new drugs. As per the reports by the World Health Organization (WHO), as many as 90% of the people suffering from HBV and HCV would be tested by 2030 and around 80% would receive treatment among them.

The HPV segment, however, is expected to expand at a healthy growth rate during the forecast period owing to the usage of cost-effective drugs for the treatment of infectious diseases and an increase in the incidence of HPV. Reports by WHO suggest that the most common type of sexually transmitted disease is HPV, yet there is no treatment available for HPV for now. However, HPV with mild symptoms such as genital warts can be treated with the help of anti-infective drugs.

Infectious Disease Therapeutics Market

Asia pacific is expected to expand at a fast CAGR

In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America dominated the market holding a revenue share of over 33.8% in 2019 and is anticipated to constitute a major market share in the coming years owing to favorable policies for reimbursement system and an increase in the incidence of infectious diseases in the region. Moreover, the presence of high numbers of manufacturers especially in the U.S. and rising performance of clinical trials in order to develop new drugs are key drivers that contribute to the growth of the regional market.

On the other hand, the market of Asia Pacific is expected to expand at a fast CAGR during the forecast period owing to an increase in the incidence of cases such as malaria, HIV, TB, and several other infections. The further growth of the market is attributed to healthcare initiatives taken by governments across the region to raise funds for the treatment of such diseases.

Infectious Disease Therapeutics Market

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Infectious Disease Therapeutics Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Infectious Disease Therapeutics Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Infectious Disease Therapeutics Market - Supply Chain
  4.5. Global Infectious Disease Therapeutics Market Forecast
     4.5.1. Infectious Disease Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Infectious Disease Therapeutics Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Infectious Disease Therapeutics Market Absolute $ Opportunity
5. Global Infectious Disease Therapeutics Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Infectious Disease Therapeutics Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Infectious Disease Therapeutics Demand Share Forecast, 2019-2026
6. North America Infectious Disease Therapeutics Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Infectious Disease Therapeutics Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Infectious Disease Therapeutics Demand Share Forecast, 2019-2026
7. Latin America Infectious Disease Therapeutics Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Infectious Disease Therapeutics Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Infectious Disease Therapeutics Demand Share Forecast, 2019-2026
8. Europe Infectious Disease Therapeutics Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Infectious Disease Therapeutics Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Infectious Disease Therapeutics Demand Share Forecast, 2019-2026
9. Asia Pacific Infectious Disease Therapeutics Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Infectious Disease Therapeutics Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Infectious Disease Therapeutics Demand Share Forecast, 2019-2026
10. Middle East & Africa Infectious Disease Therapeutics Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Infectious Disease Therapeutics Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Infectious Disease Therapeutics Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Infectious Disease Therapeutics Market: Market Share Analysis
  11.2. Infectious Disease Therapeutics Distributors and Customers
  11.3. Infectious Disease Therapeutics Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. GlaxoSmithKline PLC Gilead Novartis AG Janssen Pharmaceutical, Inc. Merck & Co. Inc. F. Hoffmann-La Roche Ltd.

Segments Covered in the Report

The global infectious disease therapeutics market has been segmented on the basis of

Disease Types

  • HIV
    • Aptivus
    • Selzentry
    • Emtriva
    • Lexiva/Telzir
    • Insentress
    • Tivicay
    • Complera
    • Odefseu
    • Atripla
    • Genvoya
    • Vitekta
    • Stribild
    • Descovy
    • Triumeq
    • Truvada
    • Others
  • Malaria
    • Coartem
    • Others
  • TB
    • Sirturu
    • Others
  • Influenza
    • Tamiflu
    • Relenza
    • Rapivab
    • Others
  • HPV
  • Hepatitis

 Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • GlaxoSmithKline PLC
  • Gilead
  • Novartis AG
  • Janssen Pharmaceutical, Inc.
  • Merck & Co. Inc.
  • F. Hoffmann-La Roche Ltd.
  • Boehringer Ingelheim GmbH
  • BioCryst Pharmaceuticals, Inc.

Key players competing in the global infectious disease therapeutics market are GlaxoSmithKline PLC; Gilead; Novartis AG; Janssen Pharmaceutical, Inc.; Merck & Co. Inc.; F. Hoffmann-La Roche Ltd.; Boehringer Ingelheim GmbH; and BioCryst Pharmaceuticals, Inc. Many of these players have adopted business strategies such as the development of new drugs, the advancement of technologies, mergers, partnerships, and production capacity expansion to increase their market position and expand their consumer base globally.

Infectious Disease Therapeutics Market

Buy Report